Posted by Michael Wonder on 29 Jun 2021
Costly new Alzheimer’s drug could force Medicare to restrict access
28 June 2021 - The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 a year, to limit the financial impact.
The recent approval of a high price Alzheimer’s drug raises the prospect that the federal Medicare system could threaten to sharply curtail which patients will qualify for a medicine that has limited clinical benefit but is likely to cost billions of dollars in coming years.
